Biomarin Pharmaceutical Inc (BMRN)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 942,842 | 755,127 | 724,531 | 587,276 | 649,158 |
| Short-term investments | US$ in thousands | 194,864 | 318,683 | 567,006 | 426,599 | 416,228 |
| Total current liabilities | US$ in thousands | 606,988 | 1,177,020 | 588,884 | 539,822 | 492,548 |
| Cash ratio | 1.87 | 0.91 | 2.19 | 1.88 | 2.16 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($942,842K
+ $194,864K)
÷ $606,988K
= 1.87
The cash ratio of Biomarin Pharmaceutical Inc has varied over the years based on the provided data. In December 2020, the cash ratio was 2.16, indicating that the company had $2.16 in highly liquid assets for every $1 of current liabilities. This ratio decreased to 1.86 by December 2021, suggesting a potential decrease in the company's ability to cover its short-term obligations with cash and cash equivalents.
However, the cash ratio improved in the following years, reaching 2.19 by December 2022. This increase indicates a better liquidity position for the company compared to the previous year. Subsequently, by December 2023, the cash ratio declined significantly to 0.91, signaling a potential liquidity challenge for Biomarin Pharmaceutical Inc in meeting its short-term financial obligations.
In the most recent year, December 2024, the cash ratio improved again to 1.87, indicating a better ability to cover short-term liabilities with available cash. Overall, fluctuations in the cash ratio of Biomarin Pharmaceutical Inc suggest varying levels of liquidity and the company's ability to manage short-term financial commitments over the years.
Peer comparison
Dec 31, 2024